ArticleBMC cell biology2011
Adhesion molecule periplakin is involved in cellular movement and attachment in pharyngeal squamous cancer cells.
Article in BMC cell biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Assessment of tissue homogenate levels of TGM1, PPL and KRT8 in a group of patients with HNSCC tumors and matched surgical margin samples.Frontiers in oncology · 2026Article
- The plakin family: Potential therapeutic targets for digestive system tumors.Journal of translational internal medicine · 2025Article
- Epiplakin expression dynamics during colon carcinogenesis: Correlation with proliferation.Biomolecules & biomedicine · 2024Article
- Article
- Prognostic implications of PPL expression in ovarian cancer.Discover oncology · 2022Article
- The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence.Cell communication and signaling : CCS · 2021Review
- Proteome-wide Analysis Reveals Substrates of E3 Ligase RNF146 Targeted for Degradation.Molecular & cellular proteomics : MCP · 2020Article
- The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors.Scientific reports · 2019Article
- Mammalian Plakins, Giant Cytolinkers: Versatile Biological Functions and Roles in Cancer.International journal of molecular sciences · 2018Review
- Identification of periplakin as a major regulator of lung injury and repair in mice.JCI insight · 2018Article
- Article
- Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.Scientific reports · 2016Article
- Aberrant DNA hypermethylation reduces the expression of the desmosome-related molecule periplakin in esophageal squamous cell carcinoma.Cancer medicine · 2015Article
- Hinged plakin domains provide specialized degrees of articulation in envoplakin, periplakin and desmoplakin.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe previously reported that periplakin (PPL) is downregulated in human esophageal cancer tissues compared to the adjacent non-cancer epithelium. Thus PPL could be a useful marker for detection of early esophageal cancer and evaluation of tumor progression, but largely remains unknown in this field. To investigate PPL involvement in carcinogenesis, tumor progression, cellular movement or attachment activity, siRNAs against PPL were transfected into pharyngeal squamous cancer cell lines and their effects on cellular behaviours were examined.
resultsPPL knockdown appeared to decrease tumor cell growth together with G2/M phase accumulation in cells attached to a culture dish. However, the extent of cell growth suppression, evaluated by the number of cells attached to the culture dish, was too distinctive to be explained only by cell cycle delay. Importantly, PPL knockdown suppressed cellular movement and attachment to the culture dish accompanied by decreased pAktSer473 phosphorylation. Additionally, LY294002, a PI3K inhibitor that dephosphorylates pAktSer473, significantly suppressed D562 cell migration. Thus PPL potentially engages in cellular movement al least partly via the PI3K/Akt axis.
conclusionsPPL knockdown is related to reduced cellular movement and attachment activity in association with PI3K/Akt axis suppression, rather than malignant progression in pharyngeal cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.